Announced Date: 2025-03-26 (March 26, 2025) Asset Name: PH020 (BAY 3713372) Licensor: Suzhou Puhe BioPharma (China) Licensee … [China BD 2025] Puhe BioPharma and AstraZeneca enters a 2 billion USD license on PRMT5i PH020 (BAY 3713372)Read more
[China BD 2025] Hengrui and MSD enters a 2 billion USD license for oral Lpa inhibitor HRS-5346
Announced Date: 2025-03-25 (March 25, 2025) Asset Name: HRS-5346 Licensor: Hengrui Pharma (Jiangsu Hengrui Pharmaceuticals Co., … [China BD 2025] Hengrui and MSD enters a 2 billion USD license for oral Lpa inhibitor HRS-5346Read more
[China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Announced Date: 2025-03-24 (March 24, 2025) Asset Name: UBT251 Licensor: United Laboratories (The United Laboratories International … [China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1/GIP/glucagon triple receptor agonistRead more
[Technology Collaboration] Syneron Bio and AstraZeneca enters a 3.5 billion USD Collaboration on oral macrocyclic peptide drug research
Announced Date: 2025-03-21 (March 21, 2025) Licensor: Syneron Bio (China) Licensee: AstraZeneca（UK） Collaboration Object: Co-develop potential … [Technology Collaboration] Syneron Bio and AstraZeneca enters a 3.5 billion USD Collaboration on oral macrocyclic peptide drug researchRead more
[China BD 2025] CSPC and Radiance enters a 1.24 billion USD license on ROR1 ADC SYS6005 (RB-164)
Announced Date: 2025-02-19 (February 19, 2025) Asset Name: SYS6005 (RB-164) Licensor: CSPC Pharmaceutical Group (China) together … [China BD 2025] CSPC and Radiance enters a 1.24 billion USD license on ROR1 ADC SYS6005 (RB-164)Read more
[China BD 2025] Lepu Biopharma and ArriVent enters a 1.2 billion USD License on CDH17 ADC MRG007
Announced Date: 2025-01-22 (January 22, 2025) Licensor (Seller): Lepu Biopharma (China) Licensee (Buyer): ArriVent BioPharma (US) … [China BD 2025] Lepu Biopharma and ArriVent enters a 1.2 billion USD License on CDH17 ADC MRG007Read more
[China BD 2025] Simcere Zaiming and AbbVie enters a 1 billion license on CFBi GPRC5D/BCMA/CD3 TsAbs SIM0500
Announced Date: 2025-01-13 (January 13, 2025) Asset Name: SIM0500 Licensor: Simcere Zaiming (a subsidiary of Simcere … [China BD 2025] Simcere Zaiming and AbbVie enters a 1 billion license on CFBi GPRC5D/BCMA/CD3 TsAbs SIM0500Read more
[China BD 2025] Insilico Medicine and Menarini (Stemline) enters a 570 million USD license on a preclinical small molecule asset
Announced Date: 2025-01-10 (January 10, 2025) Asset Name: Undisclosed Licensor: InSilico Medicine (China) Licensee (Buyer): Stemline … [China BD 2025] Insilico Medicine and Menarini (Stemline) enters a 570 million USD license on a preclinical small molecule assetRead more
[China BD 2025] Sciwind Biosciences and Verdiva Bio enters 2.47 Billion USD License on Three Metabolic Diseases Product Candidates
Announced Date: 2025-01-10 ( January 10, 2025) Licensor (Seller): Sciwind Biosciences (China) Licensee (Buyer): Verdiva Bio (US) … [China BD 2025] Sciwind Biosciences and Verdiva Bio enters 2.47 Billion USD License on Three Metabolic Diseases Product CandidatesRead more
[China BD 2025] DualityBio and Avenzo enters a 1.2 billion USD license for EGFR/HER3 BsADC DB-1418 (AVZO-1418)
Announced Date: 2025-01-07 (January 7, 2025) Asset Name: DB-1418 (AVZO-1418) Licensor (Seller): Duality Biotherapeutics (China) Licensee (Buyer): … [China BD 2025] DualityBio and Avenzo enters a 1.2 billion USD license for EGFR/HER3 BsADC DB-1418 (AVZO-1418)Read more